Postvaccination Symptoms After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease : A Prospective, Comparative Study
© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Vaccine hesitancy is prevalent among people with IBD, in part due to insufficient evidence regarding comparative safety of vaccines in this population.
METHODS: We conducted a nationwide comparative study of postvaccination symptoms among those with IBD and health care workers (HCWs) without IBD. Symptom frequency, severity, and duration were measured. Continuous and categorical data were analyzed using Wilcoxon rank-sum and Fisher's exact test. Regression analysis was used to adjust for confounding variables.
RESULTS: We had 2910 and 2746 subjects who completed a survey after dose 1 (D1) and dose 2 (D2) respectively (D1: HCW = 933, IBD = 1977; D2: HCW = 884, IBD = 1862). Mean age was 43 years, 67% were female, and 23% were nonwhite; 73% received BNT162b2 (Pfizer) including almost all HCWs and 60% of IBD patients. Most postvaccine symptoms were mild and lasted ≤2 days after both doses in both groups. Health care workers experienced more postvaccination symptoms overall than IBD patients after each dose (D1: 57% vs 35%, P < .001; D2: 73% vs 50%, P < .001). Gastrointestinal symptoms were noted in IBD more frequently after D1 (5.5% vs 3%, P = .003) but not after D2 (10% vs 13%, P = .07). Inflammatory bowel disease subjects who received mRNA-1273 (Moderna) reported more overall symptoms compared with BNT162b2 (57% vs 46%, P < .001) including gastrointestinal symptoms (12% vs 8%, P = .002) after D2.
CONCLUSIONS: People with IBD had fewer postvaccination symptoms following the first 2 doses of SARS-CoV-2 mRNA vaccines than HCWs. Among those with symptoms, most symptoms were mild and of short duration.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Inflammatory bowel diseases - 30(2024), 4 vom: 03. Apr., Seite 602-616 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mujukian, Angela [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BNT162 Vaccine |
|---|
| Anmerkungen: |
Date Completed 04.04.2024 Date Revised 04.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ibd/izad114 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360560105 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360560105 | ||
| 003 | DE-627 | ||
| 005 | 20240404234243.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ibd/izad114 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM360560105 | ||
| 035 | |a (NLM)37556401 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mujukian, Angela |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Postvaccination Symptoms After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease |b A Prospective, Comparative Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2024 | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Vaccine hesitancy is prevalent among people with IBD, in part due to insufficient evidence regarding comparative safety of vaccines in this population | ||
| 520 | |a METHODS: We conducted a nationwide comparative study of postvaccination symptoms among those with IBD and health care workers (HCWs) without IBD. Symptom frequency, severity, and duration were measured. Continuous and categorical data were analyzed using Wilcoxon rank-sum and Fisher's exact test. Regression analysis was used to adjust for confounding variables | ||
| 520 | |a RESULTS: We had 2910 and 2746 subjects who completed a survey after dose 1 (D1) and dose 2 (D2) respectively (D1: HCW = 933, IBD = 1977; D2: HCW = 884, IBD = 1862). Mean age was 43 years, 67% were female, and 23% were nonwhite; 73% received BNT162b2 (Pfizer) including almost all HCWs and 60% of IBD patients. Most postvaccine symptoms were mild and lasted ≤2 days after both doses in both groups. Health care workers experienced more postvaccination symptoms overall than IBD patients after each dose (D1: 57% vs 35%, P < .001; D2: 73% vs 50%, P < .001). Gastrointestinal symptoms were noted in IBD more frequently after D1 (5.5% vs 3%, P = .003) but not after D2 (10% vs 13%, P = .07). Inflammatory bowel disease subjects who received mRNA-1273 (Moderna) reported more overall symptoms compared with BNT162b2 (57% vs 46%, P < .001) including gastrointestinal symptoms (12% vs 8%, P = .002) after D2 | ||
| 520 | |a CONCLUSIONS: People with IBD had fewer postvaccination symptoms following the first 2 doses of SARS-CoV-2 mRNA vaccines than HCWs. Among those with symptoms, most symptoms were mild and of short duration | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Covid-19 vaccine | |
| 650 | 4 | |a Crohn’s disease | |
| 650 | 4 | |a inflammatory bowel disease | |
| 650 | 4 | |a postvaccine symptoms | |
| 650 | 4 | |a ulcerative colitis | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 700 | 1 | |a Kumar, Rashmi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Dalin |e verfasserin |4 aut | |
| 700 | 1 | |a Debbas, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Botwin, Gregory J |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Ebinger, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Braun, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a McGovern, Dermot |e verfasserin |4 aut | |
| 700 | 1 | |a Melmed, Gil Y |e verfasserin |4 aut | |
| 700 | 0 | |a CORALE-IBD Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Appel, Keren |e investigator |4 oth | |
| 700 | 1 | |a Banty, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Bonthala, Nirupama |e investigator |4 oth | |
| 700 | 1 | |a Feldman, Edward |e investigator |4 oth | |
| 700 | 1 | |a Ha, Christina |e investigator |4 oth | |
| 700 | 1 | |a Reckamp, Karen |e investigator |4 oth | |
| 700 | 1 | |a Lee, Susie |e investigator |4 oth | |
| 700 | 1 | |a Merin, Noah |e investigator |4 oth | |
| 700 | 1 | |a Merchant, Akil |e investigator |4 oth | |
| 700 | 1 | |a Rabizadeh, Shervin |e investigator |4 oth | |
| 700 | 1 | |a Stein, Theodore |e investigator |4 oth | |
| 700 | 1 | |a Syal, Gaurav |e investigator |4 oth | |
| 700 | 1 | |a Targan, Stephan |e investigator |4 oth | |
| 700 | 1 | |a Vasiliauskas, Eric |e investigator |4 oth | |
| 700 | 1 | |a Ziring, David |e investigator |4 oth | |
| 700 | 1 | |a Hampton, Melissa |e investigator |4 oth | |
| 700 | 1 | |a Mengesha, Emebet |e investigator |4 oth | |
| 700 | 1 | |a Stewart, James L |e investigator |4 oth | |
| 700 | 1 | |a Frias, Edwin C |e investigator |4 oth | |
| 700 | 1 | |a Figueredo, Jane |e investigator |4 oth | |
| 700 | 1 | |a Boland, Brigid |e investigator |4 oth | |
| 700 | 1 | |a Charabaty, Aline |e investigator |4 oth | |
| 700 | 1 | |a Chiorean, Michael |e investigator |4 oth | |
| 700 | 1 | |a Cohen, Erica |e investigator |4 oth | |
| 700 | 1 | |a Ehrlich, Adam |e investigator |4 oth | |
| 700 | 1 | |a Flynn, Ann |e investigator |4 oth | |
| 700 | 1 | |a Valentine, John |e investigator |4 oth | |
| 700 | 1 | |a Fudman, David |e investigator |4 oth | |
| 700 | 1 | |a Horizon, Arash |e investigator |4 oth | |
| 700 | 1 | |a Karayev, Dmitry |e investigator |4 oth | |
| 700 | 1 | |a Kretzmann, Benjamin |e investigator |4 oth | |
| 700 | 1 | |a Glover, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Hou, Jason |e investigator |4 oth | |
| 700 | 1 | |a Hwang, Caroline |e investigator |4 oth | |
| 700 | 1 | |a Lazarev, Mark |e investigator |4 oth | |
| 700 | 1 | |a Lum, Donald |e investigator |4 oth | |
| 700 | 1 | |a Fausel, Rebecca |e investigator |4 oth | |
| 700 | 1 | |a Reddy, Swapna |e investigator |4 oth | |
| 700 | 1 | |a Mattar, Mark |e investigator |4 oth | |
| 700 | 1 | |a McConnell, Ryan |e investigator |4 oth | |
| 700 | 1 | |a Metwally, Mark |e investigator |4 oth | |
| 700 | 1 | |a Ostrov, Arthur |e investigator |4 oth | |
| 700 | 1 | |a Parekh, Nimisha |e investigator |4 oth | |
| 700 | 1 | |a Raffals, Laura |e investigator |4 oth | |
| 700 | 1 | |a Rubin, David |e investigator |4 oth | |
| 700 | 1 | |a Sheibani, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Siegel, Corey |e investigator |4 oth | |
| 700 | 1 | |a Wolf, Douglas |e investigator |4 oth | |
| 700 | 1 | |a Younes, Ziad |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammatory bowel diseases |d 1995 |g 30(2024), 4 vom: 03. Apr., Seite 602-616 |w (DE-627)NLM094498598 |x 1536-4844 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:4 |g day:03 |g month:04 |g pages:602-616 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ibd/izad114 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 4 |b 03 |c 04 |h 602-616 | ||